Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.
Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics'? proprietary and world-leading XPRESIDENT® technology.
Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients.
QUICK FACTS
- 150 Team members
- >100 Targets covering 20 major solid and liquid tumors
- About 80% of discovered targets are novel
- 2 proprietary technology platforms
- 8 proprietary development programs, thereof 2 in the clinic in 2017
- Multiple partnered programs
- Raised more than $230m in cash in five financings
Read more about Immatics on our homepage: https://immatics.com/
Find us on Twitter and XING:
Twitter: http://bit.ly/2DFbPre
XING: http://bit.ly/2E1Kkpv
Legal notice: https://immatics.com/legal-notice.html